Recurrence following radiotherapy

Frontiers of Radiation Therapy and Oncology

Volumn 41, Issue , 2008, Pages 86-92

  Desgrandchamps, F ^a  

^a SAINT LOUIS HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CONFERENCE PAPER; HUMAN; MALE; METHODOLOGY; PROSTATE TUMOR; SALVAGE THERAPY; TUMOR RECURRENCE;

HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; PROSTATIC NEOPLASMS; SALVAGE THERAPY;

EID: 49449108392     PISSN: 00719676     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000139882     Document Type: Conference Paper

References (22)

1. Swanson GP, Riggs MW, Earle JD: Long-term follow-up of radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2004;59:406-411.
2. Kuban DA, Thames HD, Shipley WU: Defining recurrence after radiation for prostate cancer. J Urol 2005;173:1871-1878.
3. Consensus statement: guidelines for PSA following radiation therapy. American Society for Therapeutic Radiology and Oncology Consensus Panel. Int J Radiat Oncol Biol Phys 1997;37:1035.
4. Crook JM, Perry GA, Robertson S, Esche BA: Routine prostate biopsies following radiotherapy for prostate cancer: results for 226 patients. Urology 1995;45:624-631.
5. Kahn D, Williams RD, Manyak MJ, Haseman MK, Seldin DW, Libertino JA, Maguire RT: 111Indium-capromab pendetide in the evaluation of patients with residual or recurrent prostate cancer after radical prostatectomy. The ProstaScint Study Group. J Urol 1998;159:2041-2046.
6. Heinisch M, Dirisamer A, Loidl W, Stoiber F, Gruy B, Haim S, Langsteger W: Positron emission tomography/computed tomography with F-18-fluorocholine for restaging of prostate cancer patients: meaningful at PSA <5 ng/ml? Mol Imaging Biol 2006;8:43-48.
7. Amling CL: Biochemical recurrence after localized treatment. Urol Clin North Am 2006;33:147-159.
8. Sartor CI, Strawderman MH, Lin XH, Kish KE, McLaughlin PW, Sandler HM: Rate of PSA rise predicts metastatic versus local recurrence after definitive radiotherapy. Int J Radiat Oncol Biol Phys 1997;38:941-947.
9. D'Amico AV, Moul JW, Carroll PR, Sun L, Lubeck D, Chen MH: Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst. 2003;95:1376-1383.
10. Sylvester J, Grimm P, Blasco J, Meier R, Spiegel J, Heaney C, Cavanagh W: The role of androgen ablation in patients with biochemical or local failure after definitive radiation therapy: a survey of practice patterns of urologists and radiation oncologists in the United States. Urology 2001;58(suppl 1):65-70.
11. Kuban DA, Thames HD, Levy LB, Horwitz EM, Kupelian PA, Martinez AA, Michalski JM, Pisansky TM, Sandler HM, Shipley WU, Zelefsky MJ, Zietman AL: Long-term multi-institutional analysis of stage T1-T2 prostate cancer treated with radiotherapy in the PSA era. Int J Radiat Oncol Biol Phys 2003;57:915-928.
12. Pinover WH, Horwitz EM, Hanlon AL, Uzzo RG, Hanks GE: Validation of a treatment policy for patients with prostate specific antigen failure after three-dimensional conformal prostate radiation therapy. Cancer 2003;97:1127-1133.
13. Tibbs MK: Wound healing following radiation therapy: a review. Radiother Oncol 1997;42:99-106.
14. Touma NJ, Izawa JI, Chin JL: Current status of local salvage therapies following radiation failure for prostate cancer. J Urol 2005;173:373-379.
15. Cresswell J, Asterling S, Chaudhary M, Sheikh N, Greene D: Third-generation cryotherapy for prostate cancer in the UK: a prospective study of the early outcomes in primary and recurrent disease. BJU Int 2006;97:969-974.
16. Grado GL, Collins JM, Kriegshauser JS, Balch CS, Grado MM, Swanson GP, Larson TR, Wilkes MM, Navickis RJ: Salvage brachytherapy for localized prostate cancer after radiotherapy failure. Urology 1999;53:2-10.
17. Beyer DC: Permanent brachytherapy as salvage treatment for recurrent prostate cancer. Urology 1999;54:880-883.
18. Gelet A, Chapelon JY, Poissonnier L, Bouvier R, Rouviere O, Curiel L, Janier M, Vallancien G: Local recurrence of prostate cancer after external beam radiotherapy: early experience of salvage therapy using high-intensity focused ultrasonography. Urology 2004;63:625-629.
19. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Theodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA, TAX 327 Investigators: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502-1512.
20. Clark PE, Hall MC, Borden LS Jr, Miller AA, Hu JJ, Lee WR, Stindt D, D'Agostino R Jr, Lovato J, Harmon M, Torti FM: Phase I-II prospective dose-escalating trial of lycopene in patients with biochemical relapse of prostate cancer after definitive local therapy. Urology 2006;67:1257-1261.
21. Woo TC, Choo R, Jamieson M, Chander S, Vieth R: Pilot study: potential role of vitamin D (cholecalciferol) in patients with PSA relapse after definitive therapy. Nutr Cancer 2005;51:32-36.
22. Pantuck AJ, Leppert JT, Zomorodian N, Aronson W, Hong J, Barnard RJ, Seeram N, Liker H, Wang H, Elashoff R, Heber D, Aviram M, Ignarro L, Belldegrun A: Phase II study of pomegranate juice for men with rising prostate-specific antigen following surgery or radiation for prostate cancer. Clin Cancer Res 2006;12:4018-4026.